Target Name: GPM6A
NCBI ID: G2823
Review Report on GPM6A Target / Biomarker Content of Review Report on GPM6A Target / Biomarker
GPM6A
Other Name(s): GPM6A variant 2 | Neuronal membrane glycoprotein M6-a | M6A | Neuronal membrane glycoprotein M6-a (isoform 1) | glycoprotein M6A | GPM6 | GPM6A_HUMAN | M6a | GPM6A variant 1 | Glycoprotein M6A, transcript variant 2 | Glycoprotein M6A, transcript variant 1

GPM6A: A Potential Drug Target for Diabetes and Other Diseases

GPM6A (GPM6A variant 2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of glomerulangioendangerteral (GED) reabsorption, which is the process by which waste products from the filtrate of the kidney are returned to the bloodstream. GPM6A is a 21-kDa protein that consists of 121 amino acid residues.

GPM6A is a protein that has been identified as a potential drug target or biomarker for a variety of diseases, including diabetes, heart failure, and neurodegenerative disorders. Several studies have suggested that GPM6A may be involved in the regulation of blood pressure, blood flow, and inflammation.

One of the key functions of GPM6A is its role in regulating GED. GED is the process by which waste products from the filtrate of the kidney are returned to the bloodstream. In individuals with diabetes, the failure of the insulin-signaling system can lead to hyperglycemia, which can damage blood vessels and contribute to the development of cardiovascular disease.

GPM6A is thought to be involved in the regulation of GED in this context. Studies have shown that GPM6A is expressed in the kidneys of individuals with diabetes and that its expression is associated with increased GED. Additionally, GPM6A has been shown to be involved in the regulation of insulin sensitivity, which is an important factor in the development of type 2 diabetes.

Another function of GPM6A is its role in the regulation of blood pressure. Studies have shown that GPM6A is expressed in the blood vessels of individuals with hypertension and that its expression is associated with increased blood pressure. Additionally, GPM6A has been shown to be involved in the regulation of inflammation, which is a key factor in the development of many diseases, including heart failure and neurodegenerative disorders.

GPM6A is also thought to be involved in the regulation of bone density, which is an important factor in the development of osteoporosis and bone fractures. Studies have shown that GPM6A is expressed in bone marrow and that its expression is associated with decreased bone density. Additionally, GPM6A has been shown to be involved in the regulation of muscle mass, which is an important factor in the development of muscle weakness and wasting in older adults.

GPM6A is a 21-kDa protein that consists of 121 amino acid residues. It is expressed in various tissues of the body, including the brain, heart, and kidneys. GPM6A is thought to be involved in the regulation of GED, blood pressure, inflammation, and bone density. As a potential drug target or biomarker, GPM6A is being studied for its potential therapeutic applications in a variety of diseases.

Protein Name: Glycoprotein M6A

Functions: Involved in neuronal differentiation, including differentiation and migration of neuronal stem cells. Plays a role in neuronal plasticity and is involved in neurite and filopodia outgrowth, filopodia motility and probably synapse formation. GPM6A-induced filopodia formation involves mitogen-activated protein kinase (MAPK) and Src signaling pathways. May be involved in neuronal NGF-dependent Ca(2+) influx. May be involved in regulation of endocytosis and intracellular trafficking of G-protein-coupled receptors (GPCRs); enhances internalization and recycling of mu-type opioid receptor

The "GPM6A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPM6A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2